Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05639933 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
A Phase 2 study of Acneiform Eruption Due to Chemical and Xerosis Cutis, sponsored by Hoth Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 8
- Study locations
NCT05639933 is a Phase 2 study of Acneiform Eruption Due to Chemical and Xerosis Cutis that is actively recruiting participants, run by Hoth Therapeutics. The registered enrollment target is 152 participants. The trial reports 8 study locations across 5 states.
The verdict
NCT05639933, a Phase 2 study of Acneiform Eruption Due to Chemical and Xerosis Cutis, is actively recruiting participants, sponsored by Hoth Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are: * Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Factor inhibitor (EGFRI) therapy using the acneiform rash investigator's global assessment scale \[ARIGA\] * Evaluate the safety of HT-001 during treatment Participants will apply HT-001 Gel once per day for 6 weeks, during which the effect on treating acneiform rash or other skin disorders induced by EGFRI therapy will be evaluated using different assessment tools to measure severity of rash, pain, and itching (pruritus), as well as the change in quality of life. The study will be completed in 2 periods: the first period is open-label (unblinded) and all patients will receive HT-001 topical gel with the active ingredient; the second period is blinded and patients will be randomized to receive one of three concentrations of HT-001 or placebo. Researchers will compare HT-001 to the placebo in the second period to see if HT-001 provides a significant treatment effect.
Conditions Studied
Interventions
- DRUG HT-001 2% Topical Gel
- DRUG HT-001 1% Topical Gel
- DRUG HT-001 0.5% Topical Gel
- DRUG HT-001 Placebo
Study Locations (8)
New York
- NYU Langone Health - Mineola
- Northwell Physician Partners Dermatology - New Hyde Park
- Montefiore Medical Center - The Bronx
California
- UCI Health - CIACC - Irvine
- UC Irvine - Chao Family Cancer Center - Orange
District of Columbia
- The George Washington University Medical Faculty Associates - Washington D.C.
Massachusetts
- Dana Farber Cancer Institute - Boston
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05639933
The ClinicalTrials.gov registry entry for NCT05639933 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoth Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acneiform Eruption Due to Chemical appearing as the primary indexed condition, and to 4 interventions - of which HT-001 2% Topical Gel is the first listed.
NCT05639933 reports 8 study locations spanning 5 distinct geographic areas - top geographies include New York, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05639933 about?
NCT05639933 is a clinical study titled "Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors". The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are: * Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Facto...
What is the current status of trial NCT05639933?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2023-07-19. Estimated completion is 2026-12-30.
What conditions does trial NCT05639933 study?
This clinical trial studies the following conditions: Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia.
What interventions are being tested in trial NCT05639933?
The interventions under investigation include: HT-001 2% Topical Gel (DRUG), HT-001 1% Topical Gel (DRUG), HT-001 0.5% Topical Gel (DRUG), HT-001 Placebo (DRUG).
Who is sponsoring clinical trial NCT05639933?
This trial is sponsored by Hoth Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05639933 being conducted?
This trial has 8 study locations across California, District of Columbia, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.